Vivani Medical shares jump 11.92% premarket after investor presentation highlights subdermal implant technology, $139B GLP-1 market potential, and 20% preclinical weight loss.

Vivani Medical surged 11.92% in premarket trading following an insider purchase of $5.999 million in shares and the release of a 2025 investor presentation highlighting its differentiated GLP-1 subdermal implant pipeline. The presentation emphasized the company’s NanoPortal technology, which offers a long-acting, in-office implantable solution addressing poor medication adherence and tolerability issues in obesity treatment. It also underscored preclinical data showing sustained weight loss and liver fat reduction, alongside a projected GLP-1 market growth to $139 billion by 2030. The insider buying signaled confidence in the company’s strategic positioning to capture underserved patient segments and reduce treatment costs compared to injectables, aligning with the stock’s sharp premarket rise.